CD133, a well-recognized stem cell biomarker, has been isolated in various tumors, including CRC, being considered a predictive factor associated with resistance to chemotherapy and radiotherapy [25,46,48,49]. The gene discussed is PROM1; the disease is colorectal carcinoma.